All publications
Carving out a Niche in Pharmaceutical Drug Delivery
Pharma Times – Vol. 53 – No. 12 - Dec 2021
A 3D-Printed Polymer–Lipid-Hybrid Tablet towards the Development of Bespoke SMEDDS Formulations
Pharmaceutics 2021, 13, 2107 https://doi.org/10.3390/pharmaceutics13122107 - Dec 2021
Solubility and Stability of Delta-9-Tetrahydrocannabinol in Lipid Excipients
CRS Annual Meeting - virtual - Jul 2021
Selecting efficient pharmaceutical binder for developing robust extended-release matrices of Compritol® 888 ATO prepared using wet granulation technique: Part 1 Studying impact on granule & tablet properties
CRS Annual Meeting - virtual - Jul 2021
Selecting efficient pharmaceutical binder for developing robust extended-release matrices of Compritol® 888 ATO prepared using wet granulation technique: Part 2 Studying impact on dissolution profiles of ER tablets of different API’s
CRS Annual Meeting - virtual - Jul 2021
Selecting efficient pharmaceutical binder for developing robust extended-release matrices of Compritol® 888 ATO prepared using wet granulation technique: Part 1 Studying impact on granule & tablet properties
CRS Annual Meeting - virtual - Jul 2021
GELUCIRE® 4414 for type IV lipid based formulations and their in vitro in vivo performance evaluation
AAPS PharmSci360 – Philadelphia (USA) - 2021
In this study, Gelucire® 44/14 in type IV lipid-based formulation has been evaluated to increase the solubility and in vivo performance of ticagrelor.
Solid lipid nanocarriers to increase oral bioavailability of the peptide Leuprolide
PBP World Meeting - 2021
Formulation forum – A Quick Approach for Evaluation of Drug-Excipient Compatibility: Case of Acetylsalicylic Acid
Drug Development & Delivery - 2021
In this study, the authors monitor acetylsalicylic acid (ASA) hydrolysis in different formulations using UPLC and TAM with the objective of comparing these methods for agreement, speed, and efficiency in predicting drug stability. In parallel, we assess the impact of the excipient choices on the stability of the ASA.